- Home
- LDP vs TECX Comparison
LDP vs TECX Comparison
Compare LDP & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDP
- TECX
- Stock Information
- Founded
- LDP 2012
- TECX 2019
- Country
- LDP United States
- TECX United States
- Employees
- LDP N/A
- TECX N/A
- Industry
- LDP Finance Companies
- TECX
- Sector
- LDP Finance
- TECX
- Exchange
- LDP Nasdaq
- TECX Nasdaq
- Market Cap
- LDP 607.2M
- TECX 647.7M
- IPO Year
- LDP N/A
- TECX 2018
- Fundamental
- Price
- LDP $20.90
- TECX $40.45
- Analyst Decision
- LDP
- TECX Strong Buy
- Analyst Count
- LDP 0
- TECX 4
- Target Price
- LDP N/A
- TECX $74.67
- AVG Volume (30 Days)
- LDP 102.5K
- TECX 136.4K
- Earning Date
- LDP 01-01-0001
- TECX 11-07-2024
- Dividend Yield
- LDP 7.91%
- TECX N/A
- EPS Growth
- LDP N/A
- TECX N/A
- EPS
- LDP N/A
- TECX N/A
- Revenue
- LDP N/A
- TECX N/A
- Revenue This Year
- LDP N/A
- TECX N/A
- Revenue Next Year
- LDP N/A
- TECX N/A
- P/E Ratio
- LDP N/A
- TECX N/A
- Revenue Growth
- LDP N/A
- TECX N/A
- 52 Week Low
- LDP $16.16
- TECX $1.40
- 52 Week High
- LDP $20.30
- TECX $48.63
- Technical
- Relative Strength Index (RSI)
- LDP 41.58
- TECX 52.47
- Support Level
- LDP $20.77
- TECX $38.04
- Resistance Level
- LDP $21.70
- TECX $48.63
- Average True Range (ATR)
- LDP 0.28
- TECX 3.34
- MACD
- LDP -0.02
- TECX -0.54
- Stochastic Oscillator
- LDP 13.44
- TECX 22.76
About LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified, closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease.